An open-label clinical trial that compares how long it takes in total for a patient with cystic fibrosis to take a daily dose of tobramycin dry power versus nebulised forms of tobramycin or colistin

Mise à jour : Il y a 5 ans
Référence : EUCTR2012-001565-33

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To compare as a primary indicator for ease of use the mean cumulative time required to set-up the delivery device (including preparation of the treatment), administer the drug, and clean the delivery device for TIP administered with the T 326 Inhaler with the cumulative time to perform the same activities (including disinfection of the device, where applicable) for the patient’s usual (pre-study prescribed) nebulized, antibiotic treatment for P. aeruginosa.


Critère d'inclusion

  • Chronic lung infection with Pseudomonas aeruginosa in cystic fibrosis patients